BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9170145)

  • 1. Tryptamine: a possible endogenous substrate for CYP2D6.
    Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J
    Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine.
    Yu AM; Granvil CP; Haining RL; Krausz KW; Corchero J; Küpfer A; Idle JR; Gonzalez FJ
    J Pharmacol Exp Ther; 2003 Feb; 304(2):539-46. PubMed ID: 12538805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine.
    Agúndez JA; Gallardo L; Martínez C; Gervasini G; Benítez J
    Pharmacogenetics; 1998 Jun; 8(3):251-8. PubMed ID: 9682270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
    Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
    Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.
    Yu AM; Idle JR; Herraiz T; Küpfer A; Gonzalez FJ
    Pharmacogenetics; 2003 Jun; 13(6):307-19. PubMed ID: 12777961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
    Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
    Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium ozagrel on the activity of rat CYP2D6.
    Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
    Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum.
    Subehan ; Usia T; Kadota S; Tezuka Y
    Planta Med; 2006 May; 72(6):527-32. PubMed ID: 16808005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6).
    Rodrigues AD; Roberts EM
    Drug Metab Dispos; 1997 May; 25(5):651-5. PubMed ID: 9152607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.
    Obach RS; Pablo J; Mash DC
    Drug Metab Dispos; 1998 Aug; 26(8):764-8. PubMed ID: 9698290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
    Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
    Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
    Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T
    Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes.
    Zhou X; Wang Y; Or PM; Wan DC; Kwan YW; Yeung JH
    Phytomedicine; 2012 May; 19(7):648-57. PubMed ID: 22541637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen.
    Dong H; Haining RL; Thummel KE; Rettie AE; Nelson SD
    Drug Metab Dispos; 2000 Dec; 28(12):1397-400. PubMed ID: 11095574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
    Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
    Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.
    Shin JG; Soukhova N; Flockhart DA
    Drug Metab Dispos; 1999 Sep; 27(9):1078-84. PubMed ID: 10460810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528.
    Kotsuma M; Tokui T; Ishizuka-Ozeki T; Honda T; Iwabuchi H; Murai T; Ikeda T; Saji H
    Drug Metab Dispos; 2008 Mar; 36(3):529-34. PubMed ID: 18056254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
    Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
    Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
    Yu AM; Idle JR; Byrd LG; Krausz KW; Küpfer A; Gonzalez FJ
    Pharmacogenetics; 2003 Mar; 13(3):173-81. PubMed ID: 12618595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.